HALOHALOZYME THERAPEUTICS, INC.
Biological Products, (no Diagnostic Substances)
- Revenue
- $1.4B
- 38% YoY
- Operating margin
- 33.6%
- 38% YoY
- EBITDA
- $480M
- 14% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 4.1×
- $2.0B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear206% of net incomeCash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear53% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear23% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $443M | $660M | $829M | $1.0B | $1.4B | 38% |
| Operating income | $276M | $268M | $338M | $551M | $469M | 15% |
| Net income | $403M | $202M | $282M | $444M | $317M | 29% |
| Operating cash flow | $299M | $240M | $389M | $479M | $652M | 36% |
| Capex | $1M | $5M | $15M | $11M | $7M | 35% |
| Stock-based comp | $21M | $24M | $37M | $43M | $52M | 19% |
| Buybacks | $350M | $200M | $402M | $250M | $342M | 37% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $16M · 27
- Net
- −$16M
Pay vs performance
No pay-versus-performance disclosure yet.